Literature DB >> 27323683

Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients.

T J G Gevers1, D Burger, E Schipper-Reintjes, M P Kooistra, C Richter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27323683

Source DB:  PubMed          Journal:  Neth J Med        ISSN： 0300-2977            Impact factor:   1.422


× No keyword cloud information.
  3 in total

1.  Treatment of chronic hepatitis C with sofosbuvir in a hemodialysis patient: a case report.

Authors:  Marius Djoumbissie Tchoupe; Hanen Chaker; Mona Boudabbous; Salma Toumi; François Pegdebamba Kissou; Saba Gargouri; Khawla Kammoun; Faiçal Jarraya; Nabil Tahri; Soumaya Yaich; Mohamed Ben Hmida
Journal:  Pan Afr Med J       Date:  2021-02-08

2.  Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease.

Authors:  Sunil Taneja; Ajay Duseja; Arka De; Manu Mehta; Raja Ramachandran; Vivek Kumar; Harbir Singh Kohli; Krishan Lal Gupta; Radha Krishan Dhiman; Yogesh Chawla
Journal:  Dig Dis Sci       Date:  2018-02-26       Impact factor: 3.199

3.  Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis.

Authors:  Jan Sperl; Sona Frankova; Miluse Kreidlova; Dusan Merta; Monika Tothova; Julius Spicak
Journal:  Ther Clin Risk Manag       Date:  2017-06-22       Impact factor: 2.423
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.